Generating a Bispecific Antibody Drug Conjugate Targeting PRLR and HER2 with Improving the Internalization

Generating a Bispecific Antibody Drug Conjugate Targeting PRLR and HER2 with Improving the Internalization

Antibody drug conjugate (ADC) therapy has become one of the most promising approaches in cancer immunotherapy. The bispecific targeting could improve the specificity, affinity, and internalization of the ADC molecules. Prolactin preceptor (PRLR) and HER2 have crosstalk signaling in breast cancer, an...

Full description

Bibliographic Details
Main Authors: Hui-Fang Zong, Bao-Hong Zhang, Jian-Wei Zhu
Format: Article
Language:English
Published: Georg Thieme Verlag KG 2022-06-01
Series:Pharmaceutical Fronts
Subjects:
bispecific adc
prlr
her2
internalization
antitumor
Online Access:http://www.thieme-connect.de/DOI/DOI?10.1055/s-0042-1749334

Similar Items

Similar Items